The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Equels Thomas K since 2015.
This trader's CIK number is 1450324.
At the time of last reporting, Equels Thomas K was the CEO & President of Aim Immunotech Inc.. (stock ticker symbol AIM).
Also see all insider trading activities at Aim Immunotech Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | AIM | 2,207,048 | $79,564 | 0 | $0 | 0 | $0 |
| 2024 | AIM | 330,324 | $90,271 | 0 | $0 | 0 | $0 |
| 2023 | AIM | 580,575 | $200,500 | 0 | $0 | 0 | $0 |
| 2021 | AIM | 26,687 | $55,000 | 0 | $0 | 0 | $0 |
| 2020 | AIM | 37,581 | $75,001 | 0 | $0 | 0 | $0 |
| 2019 | AIM | 45,436 | $132,357 | 0 | $0 | 0 | $0 |
| 2018 | AIM | 302,887 | $79,790 | 0 | $0 | 0 | $0 |
| 2017 | AIM | 272,464 | $150,000 | 0 | $0 | 0 | $0 |
| 2016 | AIM | 397,493 | $101,337 | 0 | $0 | 0 | $0 |
| 2015 | AIM | 379,104 | $85,038 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-13 | AIM | Buy | 107 | 7.70 | 823 |
| 2025-06-12 | AIM | Buy | 103 | 8.70 | 896 |
| 2025-04-11 | AIM | Buy | 1,968,504 | .03 | 49,212 |
| 2025-04-04 | AIM | Buy | 41,000 | .06 | 2,583 |
| 2025-03-05 | AIM | Buy | 50,000 | .14 | 6,750 |
| 2025-03-04 | AIM | Buy | 44,000 | .12 | 5,060 |
| 2025-03-04 | AIM | Buy | 83,334 | .12 | 10,000 |
| 2024-11-21 | AIM | Buy | 20,000 | .21 | 4,240 |
| 2024-12-18 | AIM | Buy | 22,727 | .21 | 4,681 |
| 2024-11-20 | AIM | Buy | 85,000 | .20 | 16,915 |
| 2024-11-20 | AIM | Buy | 60,110 | .18 | 11,000 |
| 2024-09-16 | AIM | Buy | 5,000 | .30 | 1,515 |
| 2024-09-13 | AIM | Buy | 20,000 | .31 | 6,160 |
| 2024-05-06 | AIM | Buy | 61,729 | .41 | 25,000 |
| 2024-03-15 | AIM | Buy | 75,758 | .33 | 25,000 |
| 2023-11-27 | AIM | Buy | 33,861 | .44 | 15,000 |
| 2023-09-29 | AIM | Buy | 22,676 | .44 | 10,000 |
| 2023-08-25 | AIM | Buy | 8,222 | .67 | 5,500 |
| 2023-08-24 | AIM | Buy | 14,993 | .67 | 10,000 |
| 2023-07-17 | AIM | Buy | 16,950 | .59 | 10,000 |
| 2023-01-03 | AIM | Buy | 161,291 | .31 | 50,000 |
| 2023-01-03 | AIM | Buy | 161,291 | .31 | 50,000 |
| 2023-01-03 | AIM | Buy | 161,291 | .31 | 50,000 |
| 2021-07-16 | AIM | Buy | 15,625 | 1.92 | 30,000 |
| 2021-02-24 | AIM | Buy | 11,062 | 2.26 | 25,000 |
| 2020-12-17 | AIM | Buy | 14,535 | 1.72 | 25,000 |
| 2020-09-03 | AIM | Buy | 12,316 | 2.03 | 25,001 |
| 2020-08-21 | AIM | Buy | 10,730 | 2.33 | 25,000 |
| 2019-06-27 | HEB | Buy | 2,632 | 4.37 | 11,501 |
| 2019-06-21 | HEB | Buy | 29,404 | 4.03 | 118,498 |
| 2019-03-19 | HEB | Buy | 13,400 | .18 | 2,358 |
| 2018-11-30 | HEB | Buy | 20,000 | .19 | 3,840 |
| 2018-10-26 | HEB | Buy | 3,500 | .20 | 710 |
| 2018-10-25 | HEB | Buy | 100,000 | .20 | 20,000 |
| 2018-07-27 | HEB | Buy | 34,483 | .29 | 10,000 |
| 2018-07-23 | HEB | Buy | 112,904 | .31 | 35,000 |
| 2018-04-27 | HEB | Buy | 32,000 | .32 | 10,240 |
| 2017-04-27 | HEB | Buy | 72,464 | .69 | 50,000 |
| 2017-04-11 | HEB | Buy | 200,000 | .50 | 100,000 |
| 2016-12-22 | HEB | Buy | 68,493 | .73 | 49,999 |
| 2016-11-01 | HEB | Buy | 10,000 | 1.00 | 10,000 |
| 2016-07-08 | HEB | Buy | 48,000 | .12 | 5,664 |
| 2016-06-29 | HEB | Buy | 59,000 | .12 | 7,080 |
| 2016-06-30 | HEB | Buy | 56,000 | .12 | 6,720 |
| 2016-07-01 | HEB | Buy | 56,000 | .12 | 6,664 |
| 2016-03-18 | HEB | Buy | 30,000 | .13 | 3,960 |
| 2016-03-11 | HEB | Buy | 40,000 | .16 | 6,360 |
| 2016-03-10 | HEB | Buy | 30,000 | .16 | 4,890 |
| 2015-08-13 | HEB | Buy | 29,104 | .18 | 5,238 |
| 2015-08-14 | HEB | Buy | 50,000 | .18 | 9,000 |
| 2015-04-27 | HEB | Buy | 100,000 | .24 | 24,400 |
| 2015-04-20 | HEB | Buy | 100,000 | .24 | 23,900 |
| 2015-04-15 | HEB | Buy | 100,000 | .23 | 22,500 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Equels Thomas K (CEO & President of Aim Immunotech Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.